Black Diamond Therapeutics Inc. (BDTX)
BDTX trades on Nasdaq in Health Care, Biotechnology: Biological Products (No Diagnostic Substances). Numbers below come from the Nasdaq screener and SEC filings, each with its source.
Price · October 14, 2026
$1.68
-5.08% on the day
Market cap
$96.5M
Micro cap
Revenue · 2025
$70.0M
No prior year to compare
Net income · 2025
$22.4B
31952.9% net margin
Price, change, market cap, sector and industry: Nasdaq stock screener, as of October 14, 2026. Revenue: SEC 10-K (us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax), period ending 2025-12-31, https://www.sec.gov/Archives/edgar/data/1701541/000170154126000009/0001701541-26-000009-index.htm. Net income: SEC 10-K (us-gaap:NetIncomeLoss), period ending 2025-12-31.
Profile
| Field | Value |
|---|---|
| Ticker | BDTX on Nasdaq |
| Sector | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) |
| Country | United States |
| IPO year | 2020 |
| SEC CIK | 0001701541 |
| SEC industry code | Biological Products, (No Diagnostic Substances) |
| Incorporated in | DELAWARE |
Financials · 2025
| Line | Value |
|---|---|
| Revenue | $70.0M |
| Net income | $22.4B |
| Operating income | $12.5M |
| Net margin | 31952.9% |
| Operating margin | 17.9% |
| Revenue growth | No prior-year revenue to compare |
| Cash | $21.0M |
| Total assets | $143.0M |
| P/E (computed) | 0.0× |
| P/S (computed) | 1.4× |
Key SEC documents
| Document | Form | Filed |
|---|---|---|
| Latest prospectus or offering document | S-3 | 2025-11-13 |
| Latest annual report | 10-K | 2026-03-16 |
| Latest quarterly / interim | 10-Q | 2026-08-05 |
| Latest current report | 8-K | 2026-08-05 |
| Latest proxy | DEFA14A | 2026-04-29 |
Source: SEC EDGAR submissions feed, 485 recent filings. All filings on EDGAR.
Peers in Biotechnology: Biological Products (No Diagnostic Substances)
| Ticker | Company | Price | Day | Market cap |
|---|---|---|---|---|
| HUMA | Humacyte Inc. | $0.3589 | -7.88% | $99.7M |
| ATRA | Atara Biotherapeutics Inc. | $9.30 | -0.80% | $93.4M |
| LENZ | LENZ Therapeutics Inc. | $3.40 | -5.82% | $106.8M |
| ENGN | enGene Therapeutics Inc. | $1.63 | -4.12% | $109.2M |
| ARMP | Armata Pharmaceuticals Inc. | $3.10 | -14.60% | $115.3M |
| TNYA | Tenaya Therapeutics Inc. | $0.5210 | -7.87% | $116.8M |
| CRDF | Cardiff Oncology Inc. | $1.01 | -2.88% | $78.6M |
| PTHS | Pelthos Therapeutics Inc. | $20.29 | +3.94% | $77.7M |
The full dossier has every filing, three years of financials, private raises and the people who signed them.
Open the full dossier